Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Class Action Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Telix securities between February 21, 2025, and August 28, 2025 [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps and Participation - Investors who suffered losses in Telix have until January 9, 2026, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit